EGFR and non-small cell lung carcinoma: In a multicenter, open-label, phase Ib TATTON study (NCT02143466), the combination of osimertinib plus savolitinib was used in the treatment of NSCLC patients harboring an EGFR mutation and MET amplification following advanced TKI treatment, which resulted in an acceptable risk–benefit profile and encouraging antitumor activity outcomes.